PMA device
INSPIRIS RESILIA Aortic Valve
Edwards Lifesciences, LLC · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision Jan 8, 2018, newest Oct 22, 2026Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
6
Naming "INSPIRIS RESILIA"
MAUDE reports
2,715
Brand "INSPIRIS RESILIA", since 2015
PubMed studies
79
Mentioning "INSPIRIS RESILIA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing INSPIRIS RESILIA Aortic Valve
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
P150048-S100 · Decided Oct 22, 2026 · 188 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
- INSPIRIS RESILIA Aortic Valve, KONECT RESILIA Aortic Valve Conduit (AVC), MITRIS RESILIA Mitral ValvePMA supplement
P150048-S077 · Decided Jan 16, 2024 · 61 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
- INSPIRIS RESILIA Aortic Valve, Model 11500APMA supplement
P150048-S073 · Decided Jul 27, 2023 · 24 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "INSPIRIS RESILIA", any status and sponsor, newest update first.
- INSPIRIS China PMCF StudyActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT05404880 · 255 participants · Start Jul 13, 2022 · Primary completion Mar 2034
Device: EDWARDS INSPIRIS RESILIA Aortic Valve · For: Aortic Valve Replacement
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 12 sites in all
Edwards LifesciencesPublic (EW)
NCT07120048 · 500 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 2026
Device: Edwards INSPIRIS RESILIA Aortic Valve · For: Aortic Valve Disease
Sites: Heidelberg, Germany; Bad Neustadt an der Saale, Germany; Erlangen, Germany · 15 sites in all
- SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.Active, not recruiting
Institut für Pharmakologie und Präventive MedizinResearch network
NCT04053088 · 500 participants (planned) · Start Dec 12, 2019 · Primary completion Oct 1, 2026
Device: INSPIRIS RESILIA Aortic Valve™ · For: Cardiovascular Diseases
Sites: Innsbruck, Austria; Linz, Austria; Salzburg, Austria · 22 sites in all
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "INSPIRIS RESILIA", and for the whole product code for context.
This brand
2,715 reports: 51 malfunction, 2,643 injury, 19 death
Whole product code LWR
17,256 reports: 871 malfunction, 15,439 injury, 934 death
Newest reports for this brand
2015691-2026-19862 · Received Oct 30, 2026 · Event dated Oct 1, 2026
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Degraded; Patient Device Interaction Problem
Patient problem as coded: Insufficient Information
2015691-2026-19863 · Received Oct 30, 2026 · Event dated Mar 10, 2026
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Unspecified Vascular Problem
2015691-2026-19866 · Received Oct 30, 2026 · Event dated Oct 6, 2026
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Degraded
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "INSPIRIS RESILIA"[tiab]. The summary above synthesizes these.
- Multicenter, propensity-weighted comparison of stented, rapid-deployment and new-generation aortic valves.
D'Onofrio A, Cibin G, Tessari C, et al. · Int J Cardiol Heart Vasc · 2024
- Inspiris Resilia in the Pulmonary Position: The Need for Discussion and Collaboration of Results.
Knox A, Gimpel D, Baker RA, et al. · Ann Thorac Surg · 2023Letter, Comment
- Inspiris Resilia Early Failure in the Pulmonary Position: Is It the Technique or the Valve?
Said SM · Ann Thorac Surg · 2023Letter, Comment
- Hemodynamic performance of INSPIRIS RESILIA aortic bioprosthesis for severe aortic stenosis: 2-year follow-up in Japanese cohort.
Fukunaga N, Yoshida S, Shimoji A, et al. · J Artif Organs · 2022
- Inspiris Resilia Valve in the Pulmonary Position: Modify or Abandon?
MacIver RH, Overman DM · Ann Thorac Surg · 2024Comment
- Thrombocytopenia Following Isolated Surgical Aortic Valve Replacement With Inspiris Resilia Bioprosthesis.
D'Alonzo M, Di Bacco L, Baudo M, et al. · Transl Med UniSa · 2024
- The use of Inspiris Resilia valves in the pulmonary position for repaired congenital heart defects.
Shikata F, Miyaji K · J Thorac Cardiovasc Surg · 2024Letter, Comment
- Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve: a retrospective comparison to the Magna Ease.
Bernard J, Georges G, Hecht S, et al. · Interdiscip Cardiovasc Thorac Surg · 2023
- Implantability of the MITRIS RESILIA Mitral Valve.
Ushijima T, Kimura S, Shiose A · Ann Thorac Surg · 2022Case Reports
- Bioprosthetic valve failure of the Inspiris Resilia valve during transcatheter valve implantation.
Kobayashi Y, Okuyama K, Kuwata S, et al. · Cardiovasc Interv Ther · 2023
- The Mitris RESILIA Valve: New Skin for a Proven Design.
Ciccarelli G, Weltert L, Scaffa R, et al. · Surg Technol Int · 2024
- Benign Intravalvular Strut Leak After Placement of the Inspiris Resilia Valve.
Berry T, Elnaggar AS, Walker JW · J Cardiothorac Vasc Anesth · 2024
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- Mitroflow Aortic Pericardial Heart ValveCorcym Canada Corp · PMA 2019
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Ats 3F Aortic Bioprosthesis Model 1000Medtronic, Inc. · PMA 2019
- Freestyle Aortic Root BioprosthesisMedtronic, Inc. · PMA 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.